ITGB3 Genotype

Your blood platelets are the first responders when a vessel is injured. They clump together, stop bleeding, and then stand down. A small genetic change can shift how aggressively that response fires, and ITGB3 (integrin beta 3) is one of the genes that helps decide.

This test reads the version of ITGB3 you inherited at birth. It is a one-time look at a fixed genetic trait that may nudge your lifetime risk of clot-related events upward or leave it untouched, depending on which variant you carry.

What ITGB3 Actually Does

ITGB3 carries the instructions for the beta 3 part of a protein on the surface of your platelets. That protein helps platelets stick to each other and to the walls of injured blood vessels. Small changes in the gene can change how easily platelets activate and clump.

The most studied variation in this gene is known as PlA1 or PlA2, also written as Leu33Pro or rs5918. Carrying the less common version has been linked, in some studies, to platelets that are quicker to activate. Other variants in the gene, such as rs3809865, have been studied in different conditions, including asthma and pregnancy loss.

Heart Attack Risk

One pooled analysis combining many studies found that carrying the PlA2 version of ITGB3 was significantly associated with myocardial infarction, the medical term for a heart attack. The link was strongest in younger people without the usual heart attack risk factors like high cholesterol, high blood pressure, or smoking. The authors of that analysis flagged significant publication bias in the overall result, meaning smaller studies showing a positive link may have been more likely to be published, so the headline effect across the full population is uncertain.

In a separate study of 7,011 people, the PlA2 variant was associated with premature myocardial infarction, meaning heart attacks happening earlier than expected. The same study did not find a link to general coronary artery disease, suggesting the variant may push platelets toward forming the actual clot that triggers an attack, rather than driving the slow buildup of plaque in the arteries.

Not every large study agrees. The Physicians' Health Study, which followed 14,916 initially healthy men for an average of 8.6 years, found no association between the PlA2 variant and heart attack, stroke, or venous blood clots, even when researchers broke the group down by age, smoking, or family history. This is a major negative result that has to be weighed against the positive findings above.

After coronary artery bypass surgery, people carrying the PlA2 variant had a higher rate of bypass graft blockage, heart attack, or death over time in a study of 261 patients. A separate study of 247 patients found no link between PlA2 and mid-term outcomes after the same surgery, so the bypass picture is mixed rather than settled.

Stroke Risk

A separate pooled analysis found that carrying the PlA2 version of ITGB3 was a risk factor for ischemic stroke, the kind caused by a clot blocking blood flow to the brain. The link was clearest for strokes that started from a clot traveling from the heart or formed in larger brain arteries.

In a study of 619 people with high blood pressure, the PlA2 variant raised the risk of ischemic stroke by about 2.9 times in the subset already classified as high risk, meaning those with three or more additional cardiovascular risk factors. It is not a finding that applies to every person with high blood pressure, but it points to how the variant can compound risk when other stressors stack up.

Why the Heart and Stroke Picture Looks the Way It Does

If you are reading the studies above and wondering why some find the variant matters while others do not, you are not alone. A meta-analysis looking at clopidogrel and aspirin response found that the PlA1/A2 variant did not reliably predict whether a person responded well to aspirin or how they did on it long-term.

The most consistent reading of the evidence is this: the variant appears to matter most in people who are otherwise considered low risk and have an early heart attack, and in people whose blood vessels are already stressed by other conditions. For everyone else, the effect is small enough that other risk factors dominate, and large healthy-population studies have found no effect at all.

Cancer Associations

In a study of 1,000 women, a specific ITGB3 genotype (called 176-CC) was linked to higher risk of breast cancer metastasis. A separate study of 755 Polish women carrying an inherited BRCA1 mutation found that the Leu33Pro variant was associated with about 2.5 times higher risk of ovarian cancer, though it did not affect breast cancer risk in the same group.

Other large studies have not confirmed a breast cancer link. A study of 5,903 people found no association between the Leu33Pro variant and breast cancer risk. A multicenter study of 15,542 BRCA1 and BRCA2 carriers found that the variant did not change breast or ovarian cancer risk in that broader population. When the original Polish cohort was excluded from the multicenter analysis, the ovarian cancer link disappeared entirely, which suggests the original Polish finding may not generalize.

The takeaway: ITGB3 variants are not a major driver of cancer risk for most people. If you carry a BRCA1 mutation, the picture is more nuanced and worth discussing with a genetics specialist.

Asthma and Allergy

Variation in ITGB3 has been linked to asthma and allergic sensitization in four separate populations, including children in the first six years of life. In a study of 636 Chinese Han children, the rs3809865 variant in ITGB3 was strongly associated with asthma. The same variant has been linked to mold allergen sensitization in adults with asthma in a study of 1,243 people.

This is a separate biological story from the clotting one. The same gene can influence different cell types in different ways, and the asthma findings come from variants distinct from the PlA1/A2 site that drives the heart and stroke associations.

Other Associations Worth Knowing

In one study of 567 people, ITGB3 was identified as a major genetic influence on whole-blood serotonin levels, with sex-specific links to lipoprotein(a), an inherited cardiovascular risk factor. A family-based study of 293 people found that a common ITGB3 haplotype was associated with autism spectrum disorder. A study of 79 patients with COVID-19 reported that an ITGB3 polymorphism was an independent risk factor for severe disease.

These connections are still being mapped, and none are mature enough to drive a clinical decision on their own. They are listed here because the same gene shows up across very different conditions, which says something about how broadly the integrin beta 3 protein touches your biology.

Reconciling the Mixed Picture

At first glance the evidence on ITGB3 looks contradictory. Some studies find a clear link between the PlA2 variant and heart attack or stroke. Others, including a large prospective study of healthy men, find no link at all, and the headline meta-analysis showing a heart attack association was itself flagged for publication bias. The simplest framework: ITGB3 is not a yes-or-no risk marker. It is a variant that may nudge platelet behavior in one direction, and that nudge appears to matter most when other risk factors are present (like high blood pressure) or absent (like in young people having unexplained early heart attacks). In the middle of the population, where other factors dominate, the effect is small or absent.

No professional society currently recommends changing cardiovascular management based on an ITGB3 result. Treat it as one piece of context, not a clinical directive.

This Is a One-Time Test

Your ITGB3 genotype was set at conception and does not change. You do not need to repeat the test. The value of the result is not in retesting; it is in using it as a permanent piece of context for cardiovascular and clotting-related decisions you make over your lifetime.

What does deserve regular tracking is the downstream phenotype: standard cardiovascular markers like ApoB (apolipoprotein B, a count of harmful cholesterol particles), Lp(a) (lipoprotein little a, an inherited cholesterol risk factor), and blood pressure. These are worth knowing whether or not you carry an ITGB3 variant. No guideline ties the cadence of those tests to your ITGB3 result, so the usual approach is to follow your clinician's general cardiovascular monitoring plan rather than escalating it on the basis of this gene alone.

What to Do With an Out-of-Pattern Result

If your test returns a higher-risk ITGB3 variant, the next step is not more genetic testing. It is a closer look at the rest of your cardiovascular risk profile. Consider an advanced lipid panel that includes ApoB and Lp(a). Check your blood pressure regularly. Know your inflammation markers like hs-CRP (high-sensitivity C-reactive protein, a measure of low-grade inflammation in your blood vessels). These are standard cardiovascular checks, not ITGB3-specific protocols, but they give you a fuller picture to share with your clinician.

If you already have a family history of early heart attack or stroke, or if you have high blood pressure, getting other risk factors under tight control is reasonable general practice, and a positive ITGB3 result is one more reason to take that seriously. If you are considering aspirin or a similar antiplatelet drug, talk with a cardiologist who is familiar with platelet genetics. A clopidogrel response variant (CYP2C19, an enzyme that activates the drug) is more reliable for predicting how you respond to that specific medication than ITGB3 is.

Share the result with biological family members. Because this is inherited, your siblings, parents, and children have a meaningful chance of carrying the same variant. They can decide whether to test as well.

When the Result Can Be Misleading

Genetic test results have their own ways of being misread. Keep these in mind:

• Panel coverage: this test reads specific variants in ITGB3, not the entire gene. A result that finds no risk variant does not rule out rarer changes in the same gene that the assay was not designed to detect.
• Ancestry matters: variant frequencies differ across populations. A finding that is common in one ancestry group can be rare in another, which changes how much weight a result deserves.
• Clinical-grade vs consumer testing: a result from a clinical lab is held to different standards than a result from a direct-to-consumer service. If you saw an ITGB3 call on a consumer report, a clinical-grade confirmation is reasonable before acting on it.
• Variants of uncertain significance: occasionally a test will flag a change in the gene whose meaning is not yet clear. That is not the same as carrying a known risk variant.

Carrying a Risk Variant Is Not a Diagnosis

A higher-risk ITGB3 variant may raise the odds of certain events. It does not guarantee you will have a heart attack, a stroke, or any other condition mentioned above. Many people carry the variant and never have an event. Many people without the variant do. The number is one input into a larger risk picture, not a verdict, and no clinical guideline currently treats it as one.